Takeda’s $30m Indonesia plasma bet starts with donors, not the drug factory
Takeda plans a $30 million Indonesia plasma network as local manufacturing stays under review. See what the deal changes for medicine access.
Pharma & Biotech
Pharma & Biotech
Could deupirfenidone beat an approved IPF drug? Celea starts the Phase 3 test that will decide
Celea Therapeutics has begun an unusually ambitious Phase 3 program designed to prove that deupirfenidone is superior, rather than merely comparable, to the established antifibrotic pirfenidone. The approximately 1,100-patient trial could support a United States registration application if successful, but its 2029 readout leaves the company facing a long development period and an increasingly competitive
Medical Devices & Diagnostics
iHealthScreen cleared a crucial FDA hurdle, but can iPredict-DR break AI eye screening’s adoption barrier?
iHealthScreen’s FDA-cleared iPredict-DR brings automated diabetic retinopathy screening closer to primary care, but adoption hurdles remain.
Pharma & Biotech
Ionis Pharmaceuticals shares slide as eplontersen misses key heart disease endpoint
See why the CARDIO-TTRansform miss complicates eplontersen’s ATTR-CM path and tests gene silencing on top of stabilizer therapy.
Medical Devices & Diagnostics
Natera just cleared a major European hurdle for Signatera, but can hospitals turn certification into adoption?
Natera’s Signatera gains European IVDR certification across multiple cancers, opening a new phase for personalized MRD testing and clinical adoption.
Pharma & Biotech
Why British Business Bank just made its biggest life sciences bet on Alchemab Therapeutics
Alchemab Therapeutics secures £25 million to double its antibody data and advance two wholly owned programs toward clinical development.
Medical Devices & Diagnostics
KKR is quietly building a medtech manufacturing powerhouse around Precipart
KKR is building Allyntra around Precipart to expand precision engineering and medical device manufacturing. See what the strategy means.
Medical Devices & Diagnostics
Bausch + Lomb is moving beyond eye-care products with an AI platform built around the patient journey
Bausch + Lomb’s Orphia brings AI to cataract education, but adoption will depend on workflow integration, validation, privacy and trust.
Medical Devices & Diagnostics
How the NeoGenomics PTEN IHC test supports targeted prostate cancer treatment
NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.
Pharma & Biotech
Apnimed files for Nasdaq IPO as oral sleep apnea drug AD109 nears FDA review
Apnimed, Inc. has filed for an initial public offering in the United States as it prepares for a potentially decisive regulatory year for AD109, its once-nightly oral treatment for obstructive sleep apnea. The Cambridge, Massachusetts-based pharmaceutical company plans to list on the Nasdaq Global Market under the ticker APMD, although the number of shares, proposed